Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome

BACKGROUND Metabolic syndrome (MetS) is prevalent in patients receiving atypical antipsychotic drugs (AADs), but there are few effective interventions. The Traditional Chinese herbal decoction Liu-Yu-Tang (LYT) has achieved clinical improvement for AAD-induced MetS, but its pharmacological mechanism remains unclear. METHOD A network pharmacology-based method was utilized in this study. First, the TCMSP and SwissTargetPrediction database were used to acquire plasma-absorbed components and putative targets of LYT, respectively. Second, an interaction network between shared targets of LYT and MetS was constructed using STRING online tool. Topological analyses were performed to extract hub gene targets. Finally, we did a pathway analysis of gene targets using the Kyoto Encyclopedia of Genes and Genomes (KEGG) to find biological pathways of LYT. RESULTS We obtained 655 putative targets of LYT, 434 known targets of AADs, and 1577 MetS-related gene targets. There are 232 shared targets between LYT and MetS. Interaction network construction and topological analysis yielded 60 hub targets, of which 18 were major hub targets, among which IL-6, IL-8, TNF, PI3K, MAPK, and NF-κB (RELA) are the most important in LYT's treatment of AAD-induced MetS. Pathway enrichment analysis revealed a statistically high significance of the AGE-RAGE signaling pathway in diabetic complications, lipid and atherosclerosis and the insulin resistance pathway. CONCLUSIONS LYT may control activities of the pro-inflammatory cytokines IL-6, IL-8, TNF and the important signal transduction molecules PI3K, MAPKs, and NF-κB (RELA), regulating metabolic disturbance-related pathways like the AGE-RAGE signaling pathway in diabetic complications, lipid and atherosclerosis, and the insulin resistance pathway, generating therapeutic effects for AAD-induced MetS.

[1]  T. Aittokallio,et al.  Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. , 2015, Natural product reports.

[2]  M. Woodward,et al.  Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? , 2015, The Journal of clinical endocrinology and metabolism.

[3]  F. Shidfar,et al.  The Impact of Low Advanced Glycation End Products Diet on Metabolic Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2020, Advances in nutrition.

[4]  Alexander Yang,et al.  Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. , 2020, The Biochemical journal.

[5]  M. Itokawa,et al.  Advanced glycation end products and schizophrenia: A systematic review. , 2015, Journal of psychiatric research.

[6]  Yun-Fei Zhang,et al.  Systematic elucidation of the mechanism of geraniol via network pharmacology , 2019, Drug design, development and therapy.

[7]  Li-li Gu,et al.  A network-based analysis of key pharmacological pathways of Andrographis paniculata acting on Alzheimer's disease and experimental validation. , 2019, Journal of ethnopharmacology.

[8]  Taolei Sun,et al.  Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate , 2019, Psychoneuroendocrinology.

[9]  X. Tong,et al.  Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: A systematic review and meta‐analysis , 2019, Diabetes, obesity & metabolism.

[10]  Vahideh Hassan-Zadeh,et al.  IL-6 signalling pathways and the development of type 2 diabetes , 2018, Inflammopharmacology.

[11]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[12]  G. Striker,et al.  Advanced glycation end products in foods and a practical guide to their reduction in the diet. , 2010, Journal of the American Dietetic Association.

[13]  W. Yao,et al.  A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.

[14]  D. Belsham,et al.  Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons , 2019, Psychoneuroendocrinology.

[15]  J. Hokanson,et al.  Hypertriglyceridemia as a cardiovascular risk factor. , 1998, The American journal of cardiology.

[16]  Chen Zhang,et al.  Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype , 2014, Psychopharmacology.

[17]  Roger Davis,et al.  The c-Jun NH2-terminal Kinase Promotes Insulin Resistance during Association with Insulin Receptor Substrate-1 and Phosphorylation of Ser307 * , 2000, The Journal of Biological Chemistry.

[18]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[19]  K. O’Shea,et al.  Radical Roles for RAGE in the Pathogenesis of Oxidative Stress in Cardiovascular Diseases and Beyond , 2013, International journal of molecular sciences.

[20]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[21]  Tsippi Iny Stein,et al.  The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses , 2016, Current protocols in bioinformatics.

[22]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[23]  Shaodong Guo Decoding insulin resistance and metabolic syndrome for promising therapeutic intervention. , 2014, The Journal of endocrinology.

[24]  Andrea Cipriani,et al.  Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis , 2020, The lancet. Psychiatry.

[25]  Anita T Layton,et al.  Network centrality analysis of eye-gaze data in autism spectrum disorder , 2019, Comput. Biol. Medicine.

[26]  A. Kuhad,et al.  Antipsychotics‐induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives , 2019, European journal of pharmacology.

[27]  Guohua Yu,et al.  Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis , 2018, BMC Complementary and Alternative Medicine.

[28]  R. Joshi,et al.  Molecular investigation of glycated insulin-induced insulin resistance via insulin signaling and AGE-RAGE axis. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[29]  Habibollah Esmaily,et al.  Cytokine and growth factor profiling in patients with the metabolic syndrome , 2015, British Journal of Nutrition.

[30]  Defeng Li,et al.  Network pharmacology-based identification of key pharmacological pathways of Yin–Huang–Qing–Fei capsule acting on chronic bronchitis , 2016, International journal of chronic obstructive pulmonary disease.

[31]  Philippe Bardou,et al.  jvenn: an interactive Venn diagram viewer , 2014, BMC Bioinformatics.

[32]  F. Koohdani,et al.  Effects of DHA-enriched fish oil on gene expression levels of p53 and NF-κB and PPAR-γ activity in PBMCs of patients with T2DM: A randomized, double-blind, clinical trial. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[33]  C. Correll,et al.  Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics , 2020, Drugs.

[34]  Guo-Qing Zheng,et al.  Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials. , 2019, Journal of psychiatric research.

[35]  G. Aldini,et al.  Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome , 2017, Nutrition & Metabolism.

[36]  Xue Xu,et al.  Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. , 2013, Journal of ethnopharmacology.

[37]  J. Manson,et al.  Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. , 1995, JAMA.

[38]  Wei Li,et al.  How Can Synergism of Traditional Medicines Benefit from Network Pharmacology? , 2017, Molecules.

[39]  C. Sukasem,et al.  Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs , 2018, The Journal of pharmacy and pharmacology.

[40]  L. Kong,et al.  High fructose diet-induced metabolic syndrome: Pathophysiological mechanism and treatment by traditional Chinese medicine. , 2018, Pharmacological research.

[41]  Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance , 2019, Scientific Reports.

[42]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[43]  H. Arnesen,et al.  Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. , 2013, Metabolism: clinical and experimental.

[44]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.